SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
CHL is strengthening its play in the fast-growing beauty and personal care sector
The Gold Medal distinction places the company in the top 5% of all organizations assessed within EcoVadis's rigorous framework globally
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month
Sun Pharma's Dadra facility receives OAI status from US FDA
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
A significant proportion of healthcare professionals still tend to favor branded drugs
Subscribe To Our Newsletter & Stay Updated
